MedWatch

Novartis books multimillion-dollar sales of Genmab-developed drug in Q1

Novartis’s sales of Kesimpta, a sclerosis drug developed by Genmab, are up by 290 percent in the first quarter of 2022 compared to Q1 2021.

Photo: ARND WIEGMANN/REUTERS / X90184

Swiss Novartis has lit a fire under its sales of Genmab-developed multiple sclerosis drug Kesimpta, evidenced by Novartis’s financial report for the first quarter of the year.

Kesimpta sales totaled USD 195m at the end of the first three months of 2022, compared to USD 50m at the conclusion of Q1, 2021.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs